https://www.prnewswire.com/news-releases/csls-phase-3-study-shows-first-in-class-garadacimab-provides-patients-with-significant-hae-attack-prevention-with-monthly-dosing-301756102.html
https://www.prnewswire.com/news-releases/csls-phase-3-study-shows...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$269.83 |
Change
-0.760(0.28%) |
Mkt cap ! $130.0B | |||
| Open | High | Low | Value | Volume |
| $269.50 | $272.00 | $268.56 | $32.70M | 121.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 39 | $269.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $269.83 | 51 | 6 |
View Market Depth
| Last trade - 12.14pm 29/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |